Results from recent Alzheimer’s disease trials validate the ProMIS approachAlzheimer's Disease, Amyloid Beta, Monoclonal Antibodies, Neurodegenerative Diseases, White PapersProMIS Neurosciences announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.” Read more February 22, 2017/by Administrator https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Administrator https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Administrator2017-02-22 12:50:412018-02-22 16:00:38Results from recent Alzheimer’s disease trials validate the ProMIS approach
